201 related articles for article (PubMed ID: 24846794)
1. High risk of hepatitis B virus reactivation in nucleos(t)ide analogue-induced hepatitis B e antigen seroconverters older than 40 years.
Kuo LF; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Chen CH
Dig Dis Sci; 2014 Oct; 59(10):2580-7. PubMed ID: 24846794
[TBL] [Abstract][Full Text] [Related]
2. Young chronic hepatitis B patients with nucleos(t)ide analogue-induced hepatitis B e antigen seroconversion have a higher risk of HBV reactivation.
Tseng TC; Liu CJ; Su TH; Yang HC; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2012 Nov; 206(10):1521-31. PubMed ID: 22966125
[TBL] [Abstract][Full Text] [Related]
3. Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion.
Chen CH; Lu SN; Lee CM; Hung CH; Wang JH; Hu TH
Hepatol Int; 2014 Jul; 8(3):365-74. PubMed ID: 26202639
[TBL] [Abstract][Full Text] [Related]
4. Combining age and HBsAg level predicts post-treatment durability of nucleos(t)ide analogue-induced HBeAg seroconversion.
Yao CC; Lee CM; Hung CH; Wang JH; Hu TH; Lu SN; Changchien CS; Hsu MC; Chen CH
J Gastroenterol Hepatol; 2015 May; 30(5):918-24. PubMed ID: 25532588
[TBL] [Abstract][Full Text] [Related]
5. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
6. Immune predictors of hepatitis B surface antigen seroconversion in patients with hepatitis B reactivation.
Islam M; Sevak JK; Sharma MK; Jindal A; Vyas AK; Bajpai M; Ramakrishna G; Sarin SK; Trehanpati N
Aliment Pharmacol Ther; 2023 Mar; 57(6):689-708. PubMed ID: 36411952
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B surface antigen level complements viral load in predicting viral reactivation in spontaneous HBeAg seroconverters.
Tseng TC; Liu CJ; Yang WT; Chen CL; Yang HC; Su TH; Wang CC; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2014 Jun; 29(6):1242-9. PubMed ID: 24384028
[TBL] [Abstract][Full Text] [Related]
8. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
9. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
[TBL] [Abstract][Full Text] [Related]
10. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
[TBL] [Abstract][Full Text] [Related]
11. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion.
Cheng Y; Guindon S; Rodrigo A; Wee LY; Inoue M; Thompson AJ; Locarnini S; Lim SG
Gut; 2013 Sep; 62(9):1347-55. PubMed ID: 23242209
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
14. Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.
Wu JF; Chiu YC; Chang KC; Chen HL; Ni YH; Hsu HY; Chang MH
Hepatology; 2016 Jan; 63(1):74-82. PubMed ID: 26389515
[TBL] [Abstract][Full Text] [Related]
15. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
[TBL] [Abstract][Full Text] [Related]
16. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion.
Wu S; Imazeki F; Kurbanov F; Fukai K; Arai M; Kanda T; Yonemitsu Y; Tanaka Y; Mizokami M; Yokosuka O
J Hepatol; 2011 Jan; 54(1):19-25. PubMed ID: 20932594
[TBL] [Abstract][Full Text] [Related]
17. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters.
Tseng TC; Liu CJ; Chen CL; Wang CC; Su TH; Kuo SF; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2012 Jan; 205(1):54-63. PubMed ID: 22095766
[TBL] [Abstract][Full Text] [Related]
18. HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients.
Song G; Yang R; Jin Q; Liu J; Rao H; Feng B; Xie Y
BMC Gastroenterol; 2023 Nov; 23(1):381. PubMed ID: 37946120
[TBL] [Abstract][Full Text] [Related]
19. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
20. A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice.
Geng M; Li Y; Gao F; Sun L; Yang X; Wang R; Chen J; Zhang Q; Wan G; Wang X
Int J Infect Dis; 2017 Sep; 62():18-25. PubMed ID: 28669850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
